Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher Approved to Trade on the OTCQB Venture Market

GlobeNewswire January 13, 2021

PharmaTher Announces Application for OTCQB Listing

GlobeNewswire December 30, 2020

PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics

GlobeNewswire December 21, 2020

Revive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin Program

GlobeNewswire December 21, 2020

PharmaTher Files U.S. Patent for Novel Combinations of Psilocybin and FDA Approved Drugs to Treat Neurological Disorders

GlobeNewswire December 15, 2020

PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson's Disease

GlobeNewswire December 10, 2020

PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson's Disease

GlobeNewswire December 8, 2020

PharmaTher & University Health Network Expand Digital Therapeutics Development

Stockhouse Editorial December 1, 2020

PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform

GlobeNewswire December 1, 2020

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

GlobeNewswire November 24, 2020

The StockTalk Cannabis Report: Nov. 20, 2020

Dave Jackson November 20, 2020

An Emerging Opportunity in Psychedelics

Stockhouse Editorial November 19, 2020

PharmaTher & Revive Therapeutics Team-Up to Investigate Psychedelic Cancer Treatment Therapies

Stockhouse Editorial November 18, 2020

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

GlobeNewswire November 18, 2020

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI(TM) Psychedelic Discovery AI Platform

GlobeNewswire November 18, 2020

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer

GlobeNewswire November 16, 2020

Prolific Parkinson's Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor

GlobeNewswire November 11, 2020

Leading Parkinson's Researcher Dr. Robert A. Hauser Joins Pharmather as Scientific Advisor

GlobeNewswire October 29, 2020

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain

GlobeNewswire October 27, 2020

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

GlobeNewswire October 22, 2020